AllPennyStocks.com Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.

Other Penny Stock Movers

Sub-Dollar Cancer Diagnostics Play Erupts on Q2 Revenue
Gold's New Bottleneck Isn't Capital; It's Equipment
Canadian Defense Tech Firm Jumps 92% as Government Revenue Boosts Margins
Most Popular
{{ index + 1 }}


Back to Top